Navigation Links
More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL

Wyeth Withdraws European Application

COLLEGEVILLE, Pa., April 23 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it is withdrawing its application for an extension to the European Marketing Authorization for TYGACIL(R) (tigecycline). This extension sought approval of TYGACIL for the treatment of community-acquired pneumonia (CAP). Wyeth's action is based on its understanding of the Committee for Medicinal Products for Human Use (CHMP) assessment that the TYGACIL CAP pivotal clinical trials did not include a sufficient number of severely ill CAP patients to alleviate reviewer concerns regarding efficacy in this subpopulation. TYGACIL is currently approved in Europe for the treatment of complicated intra-abdominal infections and complicated skin and soft tissue infections in adults.

"We are disappointed that we were not able to allay the concerns of the CHMP, and are evaluating the appropriate next steps to take in Europe," says Gary L. Stiles, M.D., Executive Vice President and Chief Medical Officer, Wyeth Pharmaceuticals. "In October 2007, the U.S. Food and Drug Administration (FDA) accepted the filing of our supplemental New Drug Application for TYGACIL for the treatment of patients with CAP. We believe that the clinical trial data submitted to the FDA, as well as other regulatory authorities around the world, demonstrate the safety and efficacy of TYGACIL for the proposed CAP indication."

The FDA is currently reviewing this application and a decision is expected during the second quarter of 2008. TYGACIL has been approved for use in patients with CAP in the Philippines and Thailand. Regulatory applications are also pending in Australia, Brazil, Canada, Switzerland and India.


TYGACIL(R) (tigecycline) is indicated for the treatment of adults with:

-- Complicated skin and skin structure infections caused by Escherichia

coli, Enterococcus faecalis (vancomycin-susceptible isolates only),

Staphylococcus aureus (methicillin-susceptible and -resistant

isolates), Streptococcus agalactiae, Streptococcus anginosus group

(includes S. anginosus, S. intermedius, and S. constellatus),

Streptococcus pyogenes, and Bacteroides fragilis

-- Complicated intra-abdominal infections caused by Citrobacter freundii,

Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella

pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates

only), Staphylococcus aureus (methicillin-susceptible isolates only),

Streptococcus anginosus group (includes S. anginosus, S. intermedius,

and S. constellatus), Bacteroides fragilis, Bacteroides

thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus,

Clostridium perfringens, and Peptostreptococcus micros

Important Safety Information

-- To reduce the development of drug-resistant bacteria and maintain the

effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should

be used only to treat infections proven or strongly suspected to be

caused by susceptible bacteria

-- Anaphylaxis/anaphylactoid reactions have been reported with nearly all

antibacterial agents, including tigecycline, and may be life-


-- TYGACIL is contraindicated in patients with known hypersensitivity to


-- TYGACIL should be administered with caution in patients with known

hypersensitivity to tetracycline class antibiotics

-- Glycylcycline class antibiotics are structurally similar to

tetracycline class antibiotics and may have similar adverse effects.

Such effects may include: photosensitivity, pseudotumor cerebri, and

anti-anabolic action (which has led to increased BUN, azotemia,

acidosis, and hyperphosphatemia). As with tetracyclines, pancreatitis

has been reported with the use of TYGACIL

-- The safety and efficacy of TYGACIL in patients with hospital-acquired

pneumonia have not been established

-- In clinical trials, the most common treatment-emergent adverse events

in patients treated with TYGACIL were nausea (29.5%) and vomiting


-- TYGACIL may cause fetal harm when administered to a pregnant woman

-- The safety and effectiveness of TYGACIL in patients below age 18 and

lactating women have not been established

-- Clostridium difficile-associated diarrhea (CDAD) has been reported with

use of nearly all antibacterial agents, including TYGACIL, and may

range in severity from mild diarrhea to fatal colitis

-- Concurrent use of antibacterial drugs with oral contraceptives may

render oral contraceptives less effective

-- The use of TYGACIL during tooth development may cause permanent

discoloration of the teeth. TYGACIL should not be used during tooth

development unless other drugs are not likely to be effective or are


-- Prothrombin time or other suitable anticoagulant test should be

monitored if TYGACIL is administered with warfarin

-- Monotherapy should be used with caution in patients with clinically

apparent intestinal perforation

-- In patients with severe hepatic impairment (Child Pugh C), the initial

dose of TYGACIL should be 100 mg followed by 25 mg every 12 hours.

Patients should be treated with caution and monitored for treatment


-- The following drugs should not be administered simultaneously through

the same Y-site as TYGACIL: amphotericin B and diazepam

Please see Prescribing Information.

Wyeth Pharmaceuticals:

Wyeth Pharmaceuticals, a division of Wyeth has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost- containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
(Date:11/26/2015)... 26, 2015 ... "2016 Future Horizons and Growth Strategies ... Market: Supplier Shares, Country Segment Forecasts, Competitive ... offering. --> ) has ... Future Horizons and Growth Strategies in the ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... Travel Representative. As a franchise owner, Somu now offers travelers, value and care ... wedding packages, private cruise sales, as well as, cabin upgrades and special amenities ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... NE (PRWEB) , ... November 26, 2015 , ... Jobs ... searched by healthcare professionals and offered by healthcare staffing agency Aureus Medical Group ... during the month of October 2015 among those searching for healthcare jobs through the ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is ... 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an ... every day excited to rebuild lives and it’s an honor to have served all ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., the ... 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by the ... Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention Center ...
Breaking Medicine News(10 mins):